<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02368613</url>
  </required_header>
  <id_info>
    <org_study_id>DW-3102_201</org_study_id>
    <nct_id>NCT02368613</nct_id>
  </id_info>
  <brief_title>A Clinical Trial for Evaluation of Adequate Dose and Safety of DW-3102 in Hypercholesterolemia Patients</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewon Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewon Pharmaceutical Co., Ltd.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate adequate-dose of DW-3102 in the treatment of&#xD;
      hypercholesterolemia patients by conducting phase 2a. 4 groups involving placebo group, each&#xD;
      groups are composed by 16, will be participated in this trial.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change of LDL-C%</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>test1 group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>DW-3102 125mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>test2 group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>DW-3102 250mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>test3 group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>DW-3102 500mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DW-3102</intervention_name>
    <arm_group_label>placebo group</arm_group_label>
    <arm_group_label>test1 group</arm_group_label>
    <arm_group_label>test2 group</arm_group_label>
    <arm_group_label>test3 group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  More than 19 years old&#xD;
&#xD;
          -  Those who meet the fasting serum lipid levels along table&#xD;
&#xD;
          -  Those who are under 350 mg/dL of TG level when fasting&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The patient of acute arterial disease&#xD;
&#xD;
          -  The patient of severe heart failure(NYHA class III or IV)&#xD;
&#xD;
          -  Within the last 6 months clinically meaningful treatment that requires that&#xD;
             arrhythmias or cardiac conduction disorders&#xD;
&#xD;
          -  Uncontrolled hypertension ( systolic blood pressure ≥ 180mmHg or diastolic blood&#xD;
             pressure ≥ 110mmHg or more later)&#xD;
&#xD;
          -  Endocrine or metabolic disease patients known to affect serum lipids or lipoproteins&#xD;
&#xD;
          -  Fibromyalgia, myopathy, rhabdomyolysis, or sudden muscle pain or have in the past,&#xD;
             such as statin (HMG CoA reductase inhibitors) in patients with muscle -related adverse&#xD;
             drug experience of the system&#xD;
&#xD;
          -  Drug malabsorption by gastrointestinal surgery experience (but simple appendectomy and&#xD;
             hernia surgery is excluded) or gastrointestinal disorders ( Crohn's disease , ulcers ,&#xD;
             acute or chronic pancreatitis , etc. )&#xD;
&#xD;
          -  Patients with history of malignancies including leukemia and lymphoma within the past&#xD;
             five years&#xD;
&#xD;
          -  If severe renal impairment or in patients with impaired liver and hematological&#xD;
             findings following the same&#xD;
&#xD;
          -  Patients who have participated in another clinical trial within the previous 30 days&#xD;
             or Prior to the administration of at least five times the half-life of the active&#xD;
             ingredient is not elapsed patient IND&#xD;
&#xD;
          -  Those having a known hypersensitivity to hyperlipidemia treatment&#xD;
&#xD;
          -  Patients with hypersensitivity or allergy to cruciferous plants&#xD;
&#xD;
          -  Patients with a history of drug or alcohol abuse within the last 12 months&#xD;
&#xD;
          -  Female patients of childbearing age&#xD;
&#xD;
          -  In the case of male test subjects , if the spouse does not agree with the use of&#xD;
             childbearing age when women work , recognized contraception exclusion criteria&#xD;
             presented in Section 15&#xD;
&#xD;
          -  Patient who are inappropriate by investigator's decision&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>February 15, 2015</study_first_submitted>
  <study_first_submitted_qc>February 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2015</study_first_posted>
  <last_update_submitted>October 7, 2016</last_update_submitted>
  <last_update_submitted_qc>October 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

